Buyer & investor transaction history
GSK acquisitions & investments
Explore 3 reviewed acquisitions & investments involving GSK as the buyer or investor. Compare transaction dates, targets, values and available valuation multiples, then open any comp for its sources and calculation basis.
Coverage includes published FundComb transactions recorded under GSK. Subsidiaries, other names and undisclosed activity may be recorded separately.
- Reviewed transactions
- 3
- With value data
- 1
- With revenue multiples
- 1
- Transaction years
- 2018
Sortable transaction comps
GSK transaction table
Rows with reported value
1 / 3
Acquisition EV, USD
-
Investment EV, USD
USD 36B
Median EV / revenue
3.6x
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
3 shown of 3 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Consumer Healthcare Control (68%) | 2018-12-19 | GlaxoSmithKline (GSK-Pfizer consumer joint venture) | Undisclosed | Undisclosed | - | - | United States & Global | Estimated 1 source | ||
| GSK Consumer Healthcare (Novartis 36.5% stake) Minority (37%) | 2018-03-27 | GlaxoSmithKline | USD 36B Estimated Enterprise Value | 35,616 | 3.6x | 20.1x | Global | Estimated 1 source | ||
| 2018-03-27 | GlaxoSmithKline plc | Undisclosed | Undisclosed | - | - | - | Confirmed 4 sources |
Explore related tags
Continue to the full transaction history for each tag.
Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.